Mycopathologia
DOI 10.1007/s11046-017-0137-5
Comparative Pathogenicity of Lomentospora prolificans
(Scedosporium prolificans) Isolates from Mexican Patients
Mariana Elizondo-Zertuche . Alexandra M. Montoya . Efrén Robledo-Leal .
Idalia Garza-Veloz . Ana L. Sánchez-Núñez . Raquel Ballesteros-Elizondo .
Gloria M. González
Received: 6 December 2016 / Accepted: 20 April 2017
Ó Springer Science+Business Media Dordrecht 2017
Abstract We identified 11 Lomentospora prolificans
isolates recovered from Mexican patients using phenotypic and molecular characteristics. The identification of isolates was assessed by internal transcribed
spacer (ITS rDNA) sequencing. In vitro susceptibility
to amphotericin B, fluconazole, voriconazole,
posaconazole, caspofungin, anidulafungin and micafungin was determined according to Clinical and
Laboratory Standards Institute (CLSI) procedures.
Three isolates (07-2239, 11-2242 and 04-2673) were
used to induce systemic infection in immunocompetent ICR mice. Survival and tissue burden studies were
M. Elizondo-Zertuche A. M. Montoya
A. L. Sánchez-Núñez G. M. González (&)
Departamento de Microbiologı́a, Facultad de Medicina,
Universidad Autónoma de Nuevo León, Madero y Dr.
Eduardo A. Pequeño s/n, Colonia Mitras Centro,
64460 Monterrey, Mexico
e-mail: gmglez@yahoo.com.mx
E. Robledo-Leal
Departamento de Microbiologı́a e Inmunologı́a, Facultad
de Ciencias Biológicas, Universidad Autónoma de Nuevo
León, San Nicolás de los Garza, Mexico
I. Garza-Veloz
Laboratorio de Medicina Molecular, Unidad Académica
de Medicina Humana y Ciencias de la Salud, Universidad
Autónoma de Zacatecas, Zacatecas, Mexico
R. Ballesteros-Elizondo
Departamento de Histologı́a, Facultad de Medicina,
Universidad Autónoma de Nuevo León, Monterrey,
Mexico
used as markers of pathogenicity. All of the strains
were resistant to every antifungal tested with MIC’s for
AmB (8–[8 lg/ml), VRC (16–[16 lg/ml), PSC (16–
[16 lg/ml), FLC (64–[64 lg/ml) and echinocandins
with MICs C8 lg/ml. One hundred, ninety and sixty
percent of the infected mice with the strains 07-2239,
11-2242 and 04-2673 died during the study, respectively. Regarding tissue burden, the highest fungal load
of the infected mice was detected in brain followed by
spleen and kidney, regardless of the strain.
Keywords Pathogenicity In vitro susceptibility
Survival study Tissue burden Lomentospora
prolificans
Introduction
Lomentospora prolificans (formerly Scedosporium
prolificans) [1] is an opportunistic filamentous mold;
it has a worldwide distribution and is frequently present
in soil, sewage and polluted waters. It is responsible for
serious infections due to its high virulence, propensity
for invasion, dissemination and multidrug resistance to
antifungals [2, 3]. Infections caused by this organism
can be localized, extended to the surrounding tissues or
disseminated to distant organs depending of the infection route and immunological status. When L. prolificans infects immunocompetent individuals, usually
having a prior trauma in the form of puncture wounds,
123
Mycopathologia
skin ulcers or surgery, it produces localized infections
that involve skin, bone and joints [4, 5]. In immunocompromised patients with cystic fibrosis, where the
most important risk factor for the acquisition of this
pathogen is inhalation and especially in those suffering
hematologic malignancies or organ-transplant recipients receiving immunosuppressive treatment, lesions
spread and they are usually fatal in less than a month.
Johnson et al. reported in 2014 that Scedosporiosis
(Scedosporium apiospermum/Lomentospora prolificans) followed lung transplantation in 55% of the cases
as well as other organ transplants (multivisceral, 18%;
heart, liver and small intestine in 45%). Scedosporiosis
was preceded by colonization in 36% of the reports.
Diseases included pneumonia (64%), mediastinitis
(18%) and fungemia/disseminated infections (18%)
[5, 6]. It is well documented that an altered immune
status of the host seems to be the main cause of invasion
by this mold, which mimics most of the pathologic
aspects of other opportunistic fungi such as Fusarium
spp., [7] Acremonium spp., [8] or Aspergillus fumigatus
[9]. In these cases, the infection is probably acquired by
inhalation of conidia and the fungus is able to develop in
practically any body organ. On the other hand, L.
prolificans shows universal in vitro and in vivo resistance to available antifungal drugs [5, 10–14] and
recovery from neutropenia has been considered a
mandatory prerequisite for resolving the infection
irrespective of the antifungal treatment used [10].
In this study, we identified 11 clinical isolates of L.
prolificans by morphological and molecular criteria.
Furthermore, we evaluated the pathogenicity of three
isolates of L. prolificans in an immunocompetent
murine model of disseminated infection.
Materials and Methods
Strains Identification
A total of 11 isolates collected over a period of
10 years (2003–2013) of L. prolificans were recovered
from a broad spectrum of clinical presentations and
identified based on their macroscopic and microscopic
morphologies and ITS rDNA sequencing. Regarding
the phenotypic approach, clinical isolates were grown
at 30 °C on potato dextrose agar (PDA) for 2 weeks.
For microscopic observation, slide cultures were made
and incubated at 30 °C for 7 days. Carbohydrates
123
assimilation was determined for sucrose, L-arabinose,
lactose, D-ribose and maltose according to a method
previously described [15]. Hydrolysis of urea was
determined using Christensen’s urea agar which was
incubated at 30 °C for 4 days, cycloheximide tolerance was determined by the isolates’ development on
Mycosel agar incubated at 30 °C for 10 days, and the
gelatinase activity was assessed in gelatin agar slants
after 20 days at 30 °C [16]. Aspartyl proteinase
activity was evaluated using bovine serum albumin
medium [17]. Phospholipase activity was carried out
on egg yolk medium [18]. Hemolytic activity was
assayed using Sabouraud blood medium [19]. In these
three last tests, plates were incubated at 30 °C for
7 days and activity was expressed in terms of presence
or absence. Thermotolerance was studied by incubating the isolates on PDA for two weeks at 30, 37 and
40 °C [16]. Candida albicans ATCC 90028 was used
as the quality control for all enzymatic activity
determinations.
In vitro susceptibility testing was performed by
the broth microdilution method for filamentous fungi
according to the CLSI document M38-A2 [20]. The
assayed antifungal agents were: amphotericin B
(AmB) (Bristol-Myers Squibb, Princeton, NJ), fluconazole (FLC) (Pfizer, Inc., New York, NY),
posaconazole (PSC) (Merck, Rahway, NJ) and
voriconazole (VRC) (Pfizer, Inc., New York, NY),
which were obtained as pure reagent-grade powders;
caspofungin (CSF), anidulafungin (ANF) and micafungin (MCF) were purchased as Cancidas (Merck
Sharp & Dohme), Eraxis (Pfizer, Inc.) and Mycamine (Astellas Pharma, Inc.), respectively. The final
concentrations of the drugs ranged from 0.125 to
64 lg/ml for FLC, from 0.03 to 16 lg/ml for VRC,
PSC and AmB and from 0.015 to 8 lg/ml for
echinocandins. The microplates were incubated at
35 °C for 72 h, and the MICs for all antifungals
were read visually. Amphotericin B, voriconazole
and posaconazole end points were determined as the
first clear well showing no growth, whereas fluconazole was read at C50% inhibition compared to the
control well. For echinocandins, MECs were determined microscopically as the lowest concentration
of drug promoting the growth of small, round,
compact hyphae relative to the appearance of the
filamentous forms seen in the control wells. Assays
were done in duplicate using Candida parapsilosis
ATCC 22019 and Paecilomyces variotii MYA 3630
AIDS acquired immunodeficiency syndrome, CML chronic myelogenous leukemia, BMT bone marrow transplantation, BAL bronchoalveolar lavage, AML acute myelogenous
leukemia, RT renal transplantation
Died d 2
Died d 3
FLC, AmB
AmB
Blood
Skin biopsy
AML, sepsis
AML
M
M
52
40
13-196
11
KJ176706
12-261
10
KJ176705
Died d 1
FLC, AmB
Peritoneal fluid, blood
AML, sepsis
M
67
07-2239
9
KJ176701
Colonization
Died d 1
AmB
None
Sputum
Blood
RT
Fibrosis cystic
F
F
57
12
11-2242
8
KJ176704
10-1167
7
KJ176703
Cured
Died d 23
Surgery
Sinus maxillaries
BAL, vitreous body
CML, sepsis
Sinusitis maxillaries
F
F
47
14
09-1125
6
KJ176702
04-2673
5
KJ176697
Died d 2
Died d 2
AmB
FLC
Blood, LCR
BAL
AML
AIDS
M
M
55
61
06-1220
4
KJ176700 KJ176697
05-2190
3
KJ176699
Died d 4
Died d 2
AmB
ITC, CAS
BAL, urine, blood
BAL
AIDS
CML, BMT
F
M
57
48
05-835
2
KJ176698
03-1714
1
KJ176696
Antifungal
treatment
Site of isolates
Underlying disease
Gender
Age
(years)
GenBank
Strain
We established two different inocula based on our own
previous in vivo studies with the strain 07-2239 of L.
prolificans, comparing the mortality rate caused by
several inocula ranging from 103 to 106 conidia/animal
and where we observed that concentrations of 1 9 105
conidia/animal and 5 9 103 conidia/animal, caused a
Patient
Experimental Disseminated Infection
Table 1 Demographic and clinical characteristics of 11 patients infected or colonized by L. prolificans
as quality control organisms. For in vitro susceptibility testing, we determined the geometric mean
and range of MICs and MECs.
For ITS rDNA sequencing, the DNA of the isolates
was extracted using the method described by González
et al. [21]. Ribosomal DNA ITS domains were
amplified using the forward primer ITS-5 (50 GGAAGTAAAAGTCGTAACAAGG-30 ) and reverse
primer ITS-4 (50 -TCCTCCGCTTATTGATATGC-30 )
[22]. Amplifications were performed in a final volume
of 30 ll containing 19 GoTaq Colorless Master Mix
(Promega, Madison, WI), 200 nM of each primer and
20 ng of DNA. The thermocycling conditions were:
94 °C for 4 min, followed by 35 cycles of 94 °C for
30 s, 53 °C for 30 s and 72 °C for 30 s, with final
extension at 72 °C for 3 min. The final products were
electrophoresed in 1.5% agarose gels and stained with
SYBRÒ Green I Gel Nucleic Acid Gel Stain (InvitrogenTM, Eugene, OR). HyperLadder I (Bioline USA
Inc.) was used as a molecular weight marker for size
determinations. The pattern of amplified bands was
photographed and analyzed with the UVP Bioimaging
System, EpiChemi III Darkroom. PCR products were
purified using the commercial Wizard SV Gel and
PCR Clean-Up system (Promega, Madison, WI).
Sequencing was performed utilizing the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems, Foster city, CA) following the manufacturer’s directions. Reactions were run and analyzed in
an Avant 3100 Genetic Analyzer (Applied Biosystems, Foster city, CA). For confirmation of phenotypic
identification, DNA sequence fragments were compared
to
ISHAM-ITS
database
(http://its.
mycologylab.org/), Mycobank (http://mycobank.org/)
and NCBI GenBank, sequence entries using BLAST.
Identifications were made when BLAST searches
yielded C99% identity. The obtained sequences are
submitted to GenBank with the accession numbers
cited in Table 1.
Outcome after
diagnosis
Mycopathologia
123
Mycopathologia
100 and 50% mortality in 2 weeks, respectively (data
not shown).
The strains from different origins selected were
04-2673, 11-2242 and 07-2239 (sinusitis maxillaries
colonization, renal transplantation and acute myelogenous leukemia) were cultured at least twice on
PDA plates to check the cultures purity and viability.
After 7 days of incubation at 30 °C, conidial cells
were harvested and washed twice in sterile saline, and
the number of conidia in the suspensions was counted
with a hemocytometer and adjusted to the desired
concentration. To corroborate the conidial counts,
serial dilutions were cultured on PDA plates at 30 °C.
Male ICR mice aged 4 weeks (weighing 20–22 g;
purchased from Harlan, Mexico) were used for the
in vivo studies. The animals were housed in cages of
five mice each. All mice were given food and water
ad libitum and were monitored daily. Care, maintenance and handling of the animals were in accordance
with the Mexican government’s license conditions for
animal experimentation and the Guidelines for the
Care and Use of Laboratory Animals. Experiments
were conducted with the approval of the Ethics and
Research Committee of Facultad de Medicina, UANL
in Monterrey, Nuevo León, Mexico (registration code
MB11-008). No immunosuppressive scheme was
used.
For the survival study, we used ten mice for each
strain. Mice received an intravenous injection of
1 9 105 conidia/animal. Deaths were registered
through day 30 post-infection. Moribund mice were
killed, and deaths were recorded as occurring on the
next day. Animals that survived to day 30 were killed
by inhalation of metofane, followed by cervical
dislocation. The spleens and brains were removed
aseptically, homogenized separately in 2 ml of sterile
phosphate-buffered saline solution (138 mM NaCl,
3 mM KCl, 8.1 mM Na2HPO4 and 1.5 mM KH2PO4),
and the entire organs were plated onto PDA and
incubated at 30 °C for 7 days to corroborate the
presence of fungi as the cause of death of the animals.
For the tissue burden study, 12 mice for each strain
received an intravenous injection of 5 9 103 conidia/
animal and groups of 4 mice per strain were sacrificed
on day 4, 7 and 10 post-infection. Half of kidneys,
spleens and brains of mice were assessed for fungal
burden by means of quantitative cultures, and the other
half of the organs were removed aseptically, weighed
and transferred to sterile glass homogenizers
123
containing 2 ml of sterile phosphate-buffered saline
solution (138 mM NaCl, 3 mM KCl, 8.1 mM Na2HPO4 and 1.5 mM KH2PO4). The organs were
mechanically homogenized (Polytron-Aggregate,
Kinematic), and serial tenfold dilutions of the suspensions were plated onto PDA and incubated at 30 °C for
7 days to determine the number of viable CFU in each
organ. Five uninfected mice were used as controls per
experimental day. The entire in vivo experiments were
performed twice at different times.
Histopathology
For the tissue burden study, after mice were killed,
tissues (half of each organ) were immediately
removed and fixed with 10% buffered formalin.
Samples were dehydrated, paraffin embedded and
sliced into 5-lm sections. The sections were stained
with Grocott methenamine silver for light microscopy
observations.
Statistics
Mean survival time (MST) was estimated by the
Kaplan–Meier method and compared among groups
by the log-rank test. The fungal tissue burdens of the
tested organs in the different experimental groups
were analyzed using the Kruskal–Wallis test in SPSS
(version 17.0 for Windows; Chicago, IL, USA) and
plotted using GraphPad Prism version 6.01 (Graph
Prism Software Inc., USA). P B 0.05 was statistically
significant.
Results
Demographic and Clinical Data
Eleven isolates of L. prolificans were registered at
Departamento de Microbiologı́a, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico, from 2003 to 2013. The demographic
data of the patients are shown in Table 1. The median
age of the patients was 52 years with a range of
12–67 years. There were a total of six males (55%)
and five females (45%). Seven out of the eleven
patients had a hematologic malignancy and/or underwent bone marrow or solid organ transplantation or
received long-term corticosteroids; this pathology was
Mycopathologia
the most common underlying disease (64%) followed
by AIDS (18%). Three of these seven patients
developed fungemia. Nine out of 11 (82%) patients
died as a result of their underlying diseases associated
with their disseminated fungal infection. Colonization
of the respiratory tract was noted on one CF (fibrosis
cystic) patient and one with chronic sinusitis.
Strain Identification
The 11 isolates had colonial and microscopic characteristics compatible with the genus Lomentospora. The
isolates grew on PDA plates at 30 °C, reaching
55–65 mm after 2 weeks; the colonies were flat, with
short mycelium and olive gray to blackish in color.
Microscopic examination of slide cultures revealed
hyaline, septate hyphae. Conidiogenous cells were
flask shaped with single or multiple oval, smooth and
brown conidia at their tips. Results of physiologic
testing demonstrated that 100% of the isolates assimilated L-arabinose, lactose and maltose, but none
assimilated sucrose and D-ribose. All isolates liquefied
gelatin, hydrolyzed urea and were producers of phospholipase but none produced aspartyl proteinases or
hemolysins. Their growth was inhibited by the presence of cycloheximide on Mycosel agar. All isolates
grew at 30, 37, and 40 °C. Based upon these features,
isolates were identified as L. prolificans [2] and further
confirmed by ITS (C99% ISHAM-ITS database) [22].
Table 2 In vitro susceptibilities of 11 strains of L. prolificans
against seven antifungals
Strain/antifungal
MIC/MEC 72 h (lg/mL)
Range
GMa
50%
90%
16–[16
L. prolificans (11)
Amphotericin B
16
16
[16
Anidulafungin
2–8
3.36
2
8
Micafungin
1–8
4
4
8
Caspofungin
1–8
4.36
4
8
Voriconazole
16–[16
16
16
16
Posaconazole
16–[16
16
[16
[16
Fluconazole
64–[64
64
[64
[64
MIC minimum inhibitory concentration, MEC minimum
effective concentration
a
Geometric mean
Fig. 1 Survival of mice infected with L. prolificans by
intravenous inoculation through the lateral vein with (1 9 105
conidia/mouse)
Antifungal Susceptibility
According to the MICs obtained, all the strains were
resistant to AmB (8[ 8 lg/ml), VRC (16–[16 lg/ml),
PSC (16–[16 lg/ml), FLC (64–[64 lg/ml). However,
echinocandins exhibited a moderate in vitro activity
against all strains when the minimum effective concentration (MEC) was used as the end point for antifungal
susceptibility testing (MEC geometric mean 3.36, 4 and
4.36 lg/ml for ANF, MCF and CSF, respectively). The
MICs of the control strains were within the acceptable range for the tested drugs (Table 2).
Experimental Disseminated Infection
The results confirmed the high virulence exhibited by
clinical strains of L. prolificans, since most of the
strains tested in the present study produced lethal
infections in all the mice (Fig. 1). One hundred
percent of the mice infected with strain 07-2239 and
90% of those infected with strain 11-2242 died
between 3–14 and 3–17 days, respectively. However,
a slight reduction in virulence was observed in the
mice infected with strain 04-2673, where animals died
between days 3 and 24 post-infection, with a 40%
survival at the end of the study. The mean survival
time (MST) in days for L. prolificans strains 07-2239,
11-2242 and 04-2673 with 95% confidence interval
(95% CI) was: 6.2 (4.18–8.22), 9.1 (4.11–14.08) and
17.8 (10.85–24.75), respectively (P \ 0.015). The
animals manifested a behavior consisting of running in
circles or gyrating by means of continuous lateral
rolling, ataxia, weight loss, ruffled hair and stiff neck
3 days before their death.
The fungal tissue burden results are summarized in
Table 3 and Fig. 2. In general, the highest fungal load
of all three strains was detected in brain followed by
123
Mycopathologia
Table 3 Fungal tissue burden results in mice intravenously infected with inocula of 5 9 103 CFU/mouse
Strain (GenBank
accession number)
Organ
Log CFU/g tissue [median (range)]
Days post-infection
4
7
10
L. prolificans
Brain
4.70 (4.25–5.08)
3.65 (3.58–3.68)
3.81 (3.71–3.86)
04-2673
Spleen
3.59 (3.49–3.88)
3.31 (3.12–3.46)
2.28 (2.22–2.44)
(KJ176697)
Kidney
2.70 (2.63–3.11)
2.59 (2.48–2.67)
2.11 (1.96–2.26)
07-2239
Brain
5.02 (4.73–5.07)
4.96 (5.40–4.60)
4.79 (4.67–5.95)
(KJ176701)
Spleen
3.75 (3.48–4.01)
3.51 (3.45–3.60)
3.22 (3.12–3.31)
Kidney
3.05 (2.99–3.14)
2.90 (2.85–2.95)
2.56 (2.45–2.82)
11-2242
Brain
4.88 (4.74–5.09)
4.73 (4.56–4.94)
4.71 (4.64–5.23)
(KJ176704)
Spleen
3.85 (3.68–3.95)
3.65 (3.55–3.66)
3.34 (3.08–3.54)
Kidney
3.10 (3.04–3.16)
2.98 (2.89–3.00)
2.55 (2.49–2.87)
Fig. 2 Graph of fungal
tissue burden results in mice
intravenously infected with
inocula of 5 9 103
CFU/mouse of the strains
tested by day 4, 7 and day 10
post-challenges
spleen and kidney tested on the three experimental
days (P = 0.4283). No significant difference was
found between different strains or separate days. There
was a slight decrease in tissue burden during the days
7–10 of the experiments (P = 0.4156), and clearance
of the fungal elements was never observed in any
studied organs. Histopathological examination
revealed the presence polymorphonuclear cells infiltration, neurons presented morphological signs of
necrosis characterized by a hyperchromic and pycnotic nucleus, and abundant presence of hyphae and
conidia in all the brain tissue samples was taken from
the dissected mice during each of the three experimental days (Fig. 3).
123
Discussion
Lomentospora prolificans can be considered as a truly
emerging dangerous pathogen; previous studies have
reported that it is associated with more severe
infections compared to those caused by other Scedosporium species and the members of the Scedosporium apiospermum species complex. Support for these
clinical finding has been demonstrated in previous
studies [26–30]. Rodrı́guez-Tudela et al. reported
patients with malignancies, disseminated infection
with L. prolificans was the most frequent (81.9%), and
it was associated with a high mortality rate 64%. This
is consistent with our results.
Mycopathologia
Fig. 3 Representative histopathological Grocott methenamine
silver-stained sections of brain from ICR mice intravenously
infected with 5 9 103 CFU/mouse of the strains tested by days
4, 7 and day 10 post-challenge showing hyphal elements,
polymorphonuclear cell infiltration and signs of necrosis
characterized by a hyperchromic and pycnotic nucleus
Most of the patients receiving immunosuppressive
therapy developed fatal disseminated infection, and
nearly all of them underwent antifungal treatment,
however; the short survival period of most of the
patients with disseminated infections is alarming. One
of the most remarkable characteristics of the infections
caused by this mold is the high rate of positive blood
cultures, as reported previously especially in patients
with disseminated infections [26]. However, the
interpretation of these positive cultures is very difficult
and may lead to misinterpretation, and many of the
blood cultures didn’t turn positive until few days
before the death of the patient, thus limiting their
diagnostic utility [5]. Despite this mold being easily
identified once isolated, the mortality of disseminated
infections is so high that new procedures allowing a
more rapid diagnosis are required.
Breakthrough L. prolificans infections are frequently found in patients with neutropenia under
antifungal prophylaxis [27]. This reflects the extreme
resistance of this species to these drugs in contrast to
other opportunistic hyphomycetes, e.g., P. boydii and
S. apiospermum. L. prolificans is known to be
multidrug resistant, especially to amphotericin B,
5-flucytosine, echinocandins and most azoles. While
there are limited data on the successful treatment of
patients with deep seated L. prolificans infection, the
combination of voriconazole and terbinafine appears to
be the most effective [28–30]. The resistance of L.
prolificans isolates to all antifungal in this study
suggests that there is a need for further studies on
susceptibility and resistance mechanisms of L. prolificans. In general, our results correlate with clinical data
because infections caused by these molds are usually
nonresponsive to antifungals and their outcomes are
usually fatal compared to S. apiospermum [10, 13, 30].
According to provisions in the guidelines of the
International Society for Human and Animal Mycology (ISHAM)-ITS database, sequencing of this region
it is sufficient to reach an accurate identification of
these microorganisms [22]. The sequencing results
presented here confirm the high similarity within L.
123
Mycopathologia
prolificans, which is known to be highly conserved at
the ITS region [31, 32].
A remarkable aspect of this study is that three of the
eleven strains tested exhibited virulence characteristics
which could be related to the pathology from which
they were isolated; the mildly virulent strain was
isolated from a sinusitis maxillaries colonization, and
the highly virulent strains were isolated from fatal
disseminated infections in patients with acute myelogenous leukemia and renal transplantation, all in
Nuevo León, México. This could indicate that strains
with different virulence patterns can exist in the same
region, in agreement with Ortoneda et al. [23]. All L.
prolificans strains studied caused similar mortality
rates and tissues infiltration as shown by histopathology examinations in the animals’ brains, spleens and
kidneys. These findings are consistent with results
from other authors [23–25], which confirms the
predilection of these fungi for brain tissues, being
more often reported in patients with disseminated
infections. The ability of L. prolificans to cause
invasive infection is also supported by its ability to
attack all visceral organs, particularly when it initiates
infection through intravenous route.
In conclusion, L. prolificans is a highly virulent
opportunistic fungus, as the clinical and experimental
data demonstrate. Due to the resistance of this fungus
to all available antifungal drugs, it is of enormous
importance to develop preventive strategies focusing
on reducing both environmental and host risk factors,
including decreasing the exposure of the airways and
reducing the risk associated with neutropenia.
Acknowledgements This research was made possible through
support from Conacyt-INFRA-2015-01 (code 251142).
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no
conflict of interest. The authors alone are responsible for the
content and the writing of the paper.
References
1. Lackner M, de Hoog GS. Proposed nomenclature for
Pseudallescheria, Scedosporium and related genera. Fungal
Divers. 2014;67:1–10.
2. De Hoog GS, Guarro J, Gene J, Figueras MJ. Hyphomycetes. Genus: Scedosporium. In: Atlas of clinical fungi, 2nd
ed. Utrecht, Centraalbureau voor Schimmelcultures,
2000:899–901.
123
3. Gosbell IB, Morris ML, Gallo JH, Weeks KS, Neville SA,
Rogers AH. Andrews rh, Ellis HD. Clinical, pathologic and
epidemiologic features of infection with Scedosporium
prolificans: four cases and review. Clin Microbiol Infect.
1999;5:672–86.
4. Panackal AA, Marr KA. Scedosporium/Pseudallescheria
infections. Semin Respir Crit Care Med. 2004;25(2):
171–81.
5. Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu
AS, Horre R, de Hoog GS, Cuenca-Estrella M. Epidemiology and outcome of Scedosporium prolificans infection, a
review of 162 cases. Med Mycol. 2009;47(4):359–70.
6. Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical
manifestations, and outcomes of Scedosporium infections
among solid organ transplant recipients. Transpl Infect Dis.
2014;16:578–87.
7. Guarro J, Gene J. Opportunistic fusarial infections in
humans. Eur J Clin Microbiol Infect Dis. 1995;14:741–54.
8. Guarro J, Gams W, Pujol I, Gene J. Acremonium species:
new emerging fungal opportunists. In vitro antifungal susceptibilities and review. Clin Infect Dis. 1997;25:1222–9.
9. Latge JP. Aspergillus fumigatus and aspergillosis. Clin
Microbiol Rev. 1999;12:310–50.
10. Ortoneda M, Capilla J, Pujol I, Pastor FJ, Mayayo E, Fernández-Ballart J, Guarro J. Liposomal amphotericin B and
granulocyte colony-stimulating factor therapy in a murine
model of invasive infection by Scedosporium prolificans.
J Antimicrob Chemother. 2002;49(3):525–9.
11. Capilla J, Yustes C, Mayayo E, Fernández B, Ortoneda M,
Pastor FJ, Guarro J. Efficacy of albaconazole (UR-9825) in
treatment of disseminated Scedosporium prolificans infection in
rabbits. Antimicrob Agents Chemother. 2003;47(6):1948–51.
12. Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ,
Curfs-Breuker I, Klaassen CH, Meis JF. Species-specific
antifungal susceptibility patterns of Scedosporium and
Pseudallescheria species. Antimicrob Agents Chemother.
2012;56(5):2635–42.
13. Wiederhold NP, Lewis RE. Antifungal activity against
Scedosporium species and novel assays to assess antifungal
pharmacodynamics against filamentous fungi. Med Mycol.
2009;47(4):422–32.
14. Tortorano AM, Richardson M, Roilides E, et al. ESCMID
and ECMM joint guidelines on diagnosis and management
of hyalohyphomycosis: Fusarium spp., Scedosporium spp.
and others. Clin Microbiol Infect. 2014;Suppl 3:27–46.
15. Yarrow D. Methods for the isolation, maintenance, and
identification of yeasts. In: Kurtzman CP, Fell JW, editors.
The yeasts: a taxonomic study. 4th ed. Amsterdam: Elsevier; 1998.
16. Espinel-Ingroff A, Goldson PR, McGinnis MR, Kerkering
TM. Evaluation of proteolytic activity to differentiate some
dematiaceous fungi. J Clin Microbiol. 1988;26:301–7.
17. Chakrabarti A, Nayak N, Talwar P. In vitro proteinase
production by Candida species. Mycopathologia.
1991;114:163–8.
18. Price MF, Wilkinson ID, Gentry LO. Plate method for
detection of phospholipase activity in Candida albicans.
Sabouraudia. 1982;20:7–14.
19. Luo G, Samaranayake LP, Yau JY. Candida species exhibit
differential in vitro hemolytic activities. J Clin Microbiol.
2001;39(8):2971–4.
Mycopathologia
20. Clinical and Laboratory Standards Institute. Reference
method for broth dilution antifungal susceptibility testing of
filamentous fungi; approved standard, 2nd ed. CLSI M38A2. Clinical and Laboratory Standards Institute, Wayne,
PA, 2008.
21. González GM, Rojas OC, Bocanegra-Garcı́a V, González
JG, Garza-González E. Molecular diversity of Cladophialophora carrionii in patients with chromoblastomycosis in
Venezuela. Med Mycol. 2013;51(2):170–7.
22. Irinyi L, Serena C, Garcı́a-Hermoso D, et al. International
Society of Human and Animal Mycology (ISHAM)-ITS
reference DNA barcoding database-the quality controlled
standard tool for routine identification of human and animal
pathogenic fungi. Med Mycol. 2015;53(4):313–37.
23. Ortoneda M, Pastor FJ, Mayayo E, Guarro J. Comparison of
the virulence of Scedosporium prolificans strains from different origins in a murine model. J Med Microbiol.
2002;51(11):924–8.
24. Nweze EI, Okafor JI. Comparative virulence of Scedosporium species in animal models. Braz J Infect Dis. 2010;
14(3):271–6.
25. Harun A, Serena C, Gilgado F, Chen SC, Meyer W. Scedosporium aurantiacum is as virulent as S. prolificans, and
shows strain-specific virulence differences, in a mouse
model. Med Mycol. 2010;48(1):S45–51.
26. Tintelnot K, Just-Nübling G, Horré R, Graf B, Sobottka I,
Seibold M, Haas A, Kaben U, De Hoog GS. A Review of
27.
28.
29.
30.
31.
32.
German Scedosporium prolificans cases from 1993 to 2007.
Med Mycol. 2009;47(4):351–8.
Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II,
Kontoyiannis DP. Scedosporium infection in a tertiary care
cancer center: a review of 25 cases from 1989–2006. Clin
Inf Dis. 2006;43:1580–684.
Del Palacio A, Garau M, Amor E, Martinez-Alonso I, Calvo
T, Carrillo-Muñoz A, Guarro J. Case reports. Transient
colonization with Scedosporium prolificans. Report of four
cases in Madrid. Mycoses. 2001;44:321–5.
Vagefi MR, Kim ET, Alvarado RG, Duncan JL, Howes EL,
Crawford JB. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J
Ophthalmol. 2005;139:370–3.
Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans
infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–3.
Wedde M, Müller D, Tintelnot K, de Hoog GS, Stahl U.
PCR based identification of clinically relevant Pseudallescheria/Scedosporium
strains.
Med
Mycol.
1998;36:61–7.
Lennon PA, Cooper CR, Salkin IF, Lee SB. Ribosomal
DNA internal transcribed spacer analysis supports synonym
of Scedosporium inflatum and Lomentospora prolificans.
J Clin Microbiol. 1994;32:2413–6.
123
View publication stats